IE32343B1 - Pharmaceutical composition - Google Patents

Pharmaceutical composition

Info

Publication number
IE32343B1
IE32343B1 IE898/68A IE89868A IE32343B1 IE 32343 B1 IE32343 B1 IE 32343B1 IE 898/68 A IE898/68 A IE 898/68A IE 89868 A IE89868 A IE 89868A IE 32343 B1 IE32343 B1 IE 32343B1
Authority
IE
Ireland
Prior art keywords
medicament
particle size
carrier
powder
effective particle
Prior art date
Application number
IE898/68A
Other languages
English (en)
Other versions
IE32343L (en
Original Assignee
Fisons Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fisons Pharmaceuticals Ltd filed Critical Fisons Pharmaceuticals Ltd
Priority to IE163/73A priority Critical patent/IE32872B1/xx
Publication of IE32343L publication Critical patent/IE32343L/xx
Publication of IE32343B1 publication Critical patent/IE32343B1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Fastening Of Light Sources Or Lamp Holders (AREA)
IE898/68A 1967-08-08 1968-07-25 Pharmaceutical composition IE32343B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
IE163/73A IE32872B1 (en) 1967-08-08 1968-07-25 Drug for use in pharmaceutical composition

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB36270/67A GB1242211A (en) 1967-08-08 1967-08-08 Pharmaceutical composition

Publications (2)

Publication Number Publication Date
IE32343L IE32343L (en) 1969-02-08
IE32343B1 true IE32343B1 (en) 1973-06-27

Family

ID=10386572

Family Applications (1)

Application Number Title Priority Date Filing Date
IE898/68A IE32343B1 (en) 1967-08-08 1968-07-25 Pharmaceutical composition

Country Status (14)

Country Link
US (1) US3634582A (cg-RX-API-DMAC7.html)
JP (1) JPS5643448B1 (cg-RX-API-DMAC7.html)
BE (1) BE718846A (cg-RX-API-DMAC7.html)
CA (1) CA946280A (cg-RX-API-DMAC7.html)
DE (2) DE1792799A1 (cg-RX-API-DMAC7.html)
DK (1) DK123276B (cg-RX-API-DMAC7.html)
FI (1) FI48973C (cg-RX-API-DMAC7.html)
FR (2) FR8142M (cg-RX-API-DMAC7.html)
GB (1) GB1242211A (cg-RX-API-DMAC7.html)
IE (1) IE32343B1 (cg-RX-API-DMAC7.html)
MY (2) MY7400330A (cg-RX-API-DMAC7.html)
NL (1) NL161984C (cg-RX-API-DMAC7.html)
NO (1) NO128307B (cg-RX-API-DMAC7.html)
SE (1) SE372420B (cg-RX-API-DMAC7.html)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1381872A (en) * 1971-06-22 1975-01-29 Fisons Ltd Pharmaceutical compositions for inhalation
BE787100A (fr) * 1971-08-06 1973-02-02 Beecham Group Ltd Composition pour le traitement de l'asthme
GB1410588A (en) * 1971-08-10 1975-10-22 Fisons Ltd Composition
DE2332663C2 (de) * 1973-06-23 1986-07-31 Schering AG, 1000 Berlin und 4709 Bergkamen Verwendung von Kortikoid-Wirkstoffen zur Inhalationstherapie
DE2535258C2 (de) * 1974-08-10 1993-06-03 Fisons Plc, Ipswich, Suffolk Inhalierbares Medikament in Pelletform
US4161516A (en) * 1975-07-25 1979-07-17 Fisons Limited Composition for treating airway disease
FI770215A7 (cg-RX-API-DMAC7.html) * 1976-01-30 1977-07-31 Fisons Ltd
CY1333A (en) * 1980-04-30 1986-10-24 Fisons Ltd Pharmaceutical compositions containing cromoglycates
BE891013A (fr) * 1980-11-05 1982-05-05 Fisons Ltd Compositions pharmaceutique
JPS59163313A (ja) * 1983-03-09 1984-09-14 Teijin Ltd 経鼻投与用ペプチドホルモン類組成物
JP2770970B2 (ja) * 1987-04-09 1998-07-02 フアイソンズ・ピーエルシー ペンタミジンを含有する医薬組成物
US5204113A (en) * 1987-04-09 1993-04-20 Fisons Plc Pharmaceutical compositions containing pentamidine
DE4140689B4 (de) * 1991-12-10 2007-11-22 Boehringer Ingelheim Kg Inhalationspulver und Verfahren zu ihrer Herstellung
ATE204750T1 (de) * 1992-06-12 2001-09-15 Teijin Ltd Pharmazeutische zubereitung zur anwendung in den atemwegen
US6794357B1 (en) 1993-06-24 2004-09-21 Astrazeneca Ab Compositions for inhalation
US6632456B1 (en) 1993-06-24 2003-10-14 Astrazeneca Ab Compositions for inhalation
US5830853A (en) 1994-06-23 1998-11-03 Astra Aktiebolag Systemic administration of a therapeutic preparation
IS1736B (is) 1993-10-01 1999-12-30 Astra Ab Aðferð og tæki sem stuðla að aukinni samloðun agna
CZ289214B6 (cs) * 1993-10-01 2001-12-12 Astra Aktiebolag Způsob zpracování jemně děleného práąkového léčiva, zařízení k provádění tohoto způsobu a aglomeráty vyrobené tímto způsobem
NL9301851A (nl) * 1993-10-26 1995-05-16 Cordis Europ Cryo-ablatie catheter.
GB9322014D0 (en) 1993-10-26 1993-12-15 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
GB9404945D0 (en) 1994-03-15 1994-04-27 Glaxo Group Ltd Pharmaceutical composition
US6102036A (en) * 1994-04-12 2000-08-15 Smoke-Stop Breath activated inhaler
US6165976A (en) 1994-06-23 2000-12-26 Astra Aktiebolag Therapeutic preparation for inhalation
DE4425255A1 (de) 1994-07-16 1996-01-18 Asta Medica Ag Formulierung zur inhalativen Applikation
US6524557B1 (en) 1994-12-22 2003-02-25 Astrazeneca Ab Aerosol formulations of peptides and proteins
JPH10511090A (ja) 1994-12-22 1998-10-27 アストラ・アクチエボラーグ 副甲状腺ホルモン,pth含有吸入用治療製剤
HUT77775A (hu) 1994-12-22 1998-08-28 Astra Aktiebolag Aeroszolformák
GB9501841D0 (en) 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
PL189855B1 (pl) * 1997-05-27 2005-09-30 Direct Haler As Urządzenie do podawania sproszkowanej substancji aktywnej
EP1119349B1 (en) * 1998-08-18 2008-07-02 The Regents Of The University Of California Epidermal growth factor receptor antagonists for treating hypersecretion of mucus in the lungs
US7354894B2 (en) * 1998-08-18 2008-04-08 The Regents Of The University Of California Preventing airway mucus production by administration of EGF-R antagonists
DE60019920T2 (de) 1999-06-05 2006-02-23 Innovata Biomed Ltd., St. Albans Verabreichungsystem für medikamente
ITMI991582A1 (it) 1999-07-16 2001-01-16 Chiesi Farma Spa Polveri costituite da particelle aventi la superficie perfettamente levigata da utilizzare come veicoli per la preparazione di miscele inala
GB9920839D0 (en) 1999-09-04 1999-11-10 Innovata Biomed Ltd Inhaler
EP1129705A1 (en) * 2000-02-17 2001-09-05 Rijksuniversiteit te Groningen Powder formulation for inhalation
PE20011227A1 (es) 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
GB0009469D0 (en) 2000-04-17 2000-06-07 Vectura Ltd Improvements in or relating to formalities for use in inhaler devices
UA75375C2 (en) * 2000-10-12 2006-04-17 Boehringer Ingelheim Pharma Method for producing powdery preparations for inhaling
MXPA02005666A (es) * 2000-10-12 2002-11-29 Boehringer Ingelheim Pharma Nuevos polvos para anhalacion que contienen tiotropio.
US20060194773A1 (en) * 2001-07-13 2006-08-31 Paratek Pharmaceuticals, Inc. Tetracyline compounds having target therapeutic activities
DE10141377A1 (de) 2001-08-23 2003-03-13 Boehringer Ingelheim Pharma Aufstreuverfahren zur Herstellung von Pulverformulierungen
AU2002333644A1 (en) * 2001-09-17 2003-04-01 Glaxo Group Limited Dry powder medicament formulations
EP1458362A4 (en) * 2001-11-19 2006-01-18 Becton Dickinson Co PHARMACEUTICAL COMPOSITIONS IN PARTICULAR FORM
GB0128148D0 (en) 2001-11-23 2002-01-16 Innovata Biomed Ltd Assembly
US6900317B2 (en) * 2002-02-19 2005-05-31 Boehringer Ingelheim Pharma Gmbh & Co. Kg Salts of the CGRP antagonist BIBN4096 and inhalable powdered medicaments containing them
US20040014679A1 (en) * 2002-02-20 2004-01-22 Boehringer Ingelheim Pharma Gmbh & Co., Kg Inhalation powder containing the CGRP antagonist BIBN4096 and process for the preparation thereof
DE10207026A1 (de) * 2002-02-20 2003-08-28 Boehringer Ingelheim Kg Pulverinhalativum, enthaltend den CGRP-Antagonisten BIBN4096 und Verfahren zu dessen Herstellung
JP2006516531A (ja) * 2002-08-21 2006-07-06 ノートン ヘルスケアー リミテッド 吸入組成物
US7763280B2 (en) 2002-11-28 2010-07-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Tiotropium containing powder formulation for inhalation
DE10255387A1 (de) * 2002-11-28 2004-06-09 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Tiotropium-haltige Pulverformulierung für die Inhalation
DE10317461A1 (de) 2003-04-16 2004-10-28 Boehringer Ingelheim Pharma Gmbh & Co. Kg Radioaktiv markierte Mikropartikel, Verfahren zu deren Herstellung und deren Verwendung
DE10338399A1 (de) * 2003-08-18 2005-03-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Mikropartikel, enthaltend den CGRP-Antagonisten 1-[N2-[3,5-Dibrom-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-Iysyl]-4-(4-pyridinyl)-piperazin, Verfahren zu deren Herstellung sowie deren Verwendung als Inhalaltionspulver
US20050043247A1 (en) * 2003-08-18 2005-02-24 Boehringer Ingelheim International Gmbh Spray-dried amorphous BIBN 4096, process for preparing and the use thereof as inhalative
US20050042178A1 (en) * 2003-08-18 2005-02-24 Boehringer Ingelheim International Gmbh Microparticles containing the CGRP-antagonist 1-[N2-[3,5-dibrom-N-[[4-(3,4-dihydro-2(1H)-oxoquinazoline-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine, process for preparing and the use thereof as inhalation powder
US20050042179A1 (en) * 2003-08-18 2005-02-24 Boehringer Ingelheim International Gmbh Inhalative powder formulations containing the CGRP-antagonist 1-[N2-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine
DE10338402A1 (de) * 2003-08-18 2005-03-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Sprühgetrocknetes, amorphes BIBN 4096, Verfahren zu dessen Herstellung sowie dessen Verwendung als Inhalativum
DE10338407A1 (de) * 2003-08-18 2005-03-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Inhalationspulver enthaltend den CGRP-Antagonisten 1-[N2-[3,5-Dibrom-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazin
DE10338403A1 (de) * 2003-08-18 2005-03-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pulverformulierung, enthaltend den CGRP-Antagonisten 1-[N2-[3,5-Dibrom-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyrindinyl)-piperazin, Verfahren zu dessen Herstellung sowie dessen Verwendung als Inhalativum
PT1699434E (pt) 2003-09-02 2011-05-03 Norton Healthcare Ltd Processo para a prepara??o de um medicamento
AR046225A1 (es) 2003-11-04 2005-11-30 Glaxo Group Ltd Compuesto de 8-azoniabiciclo(3.2.1)octano, composicion farmaceutica para el tratamiento de enfermedades mediadas por receptores de acetilcolina muscarinicos que lo comprende y uso del compuesto para preparar dicha composicion
EP1744800B1 (en) 2004-04-21 2016-06-22 Innovata Biomed Limited Inhaler
GB0409197D0 (en) 2004-04-24 2004-05-26 Innovata Biomed Ltd Device
MY144753A (en) 2004-04-27 2011-10-31 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
US7611709B2 (en) * 2004-05-10 2009-11-03 Boehringer Ingelheim Pharma Gmbh And Co. Kg 1,4 O-linked saccharose derivatives for stabilization of antibodies or antibody derivatives
US7727962B2 (en) * 2004-05-10 2010-06-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Powder comprising new compositions of oligosaccharides and methods for their preparation
US7723306B2 (en) * 2004-05-10 2010-05-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Spray-dried powder comprising at least one 1,4 O-linked saccharose-derivative and methods for their preparation
DE102004048389A1 (de) * 2004-10-01 2006-04-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Modifizierung von Oberflächen von Laktose als Hilfsstoff zur Verwendung für Pulverinhalativa
DE102004048390A1 (de) * 2004-10-01 2006-04-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Pulverinhalativa auf Basis modifizierter Laktosemischungen als Hilfsstoff
RU2007133547A (ru) 2005-02-10 2009-03-20 Глаксо Груп Лимитед (GB) Способы получения лактозы с использованием методов предварительной сортировки и приготовляемые из нее фармацевтические композиции
CN103145766B (zh) 2008-07-24 2015-02-11 乔治洛德方法研究和开发液化空气有限公司 用于沉积含过渡金属的膜的杂配型环戊二烯基过渡金属前体
US9925282B2 (en) 2009-01-29 2018-03-27 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
EP4578502A3 (en) 2009-02-26 2025-10-08 Glaxo Group Limited Pharmaceutical formulations comprising 4-{(1 r)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol
GB0921075D0 (en) 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents
PT106094A (pt) 2012-01-13 2013-07-15 Hovione Farmaciencia S A Administração por inalação de formulações com dose elevada
WO2014007773A1 (en) * 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Compositions comprising muscarinic receptor antagonist and sorbitol
WO2014007771A2 (en) 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Inhalation compositions comprising muscarinic receptor antagonist
US10111957B2 (en) 2012-07-05 2018-10-30 Arven Ilac Snayi ve Ticaret A.S. Inhalation compositions comprising glucose anhydrous
US20150174064A1 (en) * 2012-07-05 2015-06-25 Arven IIac Sanayi Ve Ticaret A.S. Compositions comprising muscarinic receptor antagonist and glucose anhydrous
JP6499077B2 (ja) 2012-10-25 2019-04-10 ザ ジェネラル ホスピタル コーポレイション アルツハイマー病と関連疾患の治療のための併用療法
GB201305825D0 (en) 2013-03-28 2013-05-15 Vectura Ltd New use
US10525005B2 (en) 2013-05-23 2020-01-07 The General Hospital Corporation Cromolyn compositions and methods thereof
MX381173B (es) 2013-10-08 2025-03-12 Ai Therapeutics Inc Rapamicina para el tratamiento de linfangioleiomiomatosis.
US10188757B2 (en) 2013-10-22 2019-01-29 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
MX394266B (es) 2014-04-04 2025-03-24 Ai Therapeutics Inc Una formulacion de rapamicina inhalable para tratar afecciones relacionadas con la edad.
WO2016057712A1 (en) 2014-10-07 2016-04-14 Lam Therapeutics, Inc. An inhalable rapamycin formulation for the treatment of pulmonary hypertension
JP2019524865A (ja) 2016-08-31 2019-09-05 ザ ジェネラル ホスピタル コーポレイション 神経変性疾患と関連する神経炎症におけるマクロファージ/ミクログリア
MX2019014671A (es) * 2017-06-28 2020-02-07 Philip Morris Products Sa Contenedor con particulas para su uso con un inhalador.
JP7202376B2 (ja) 2017-07-20 2023-01-11 エーゼットセラピーズ, インコーポレイテッド クロモリンナトリウムおよびイブプロフェンの粉末製剤
JP2021529771A (ja) 2018-07-02 2021-11-04 ザ ジェネラル ホスピタル コーポレイション クロモリンナトリウムおよびα−ラクトースの粉末製剤
EP3833964B1 (en) 2018-08-07 2023-07-26 Norton (Waterford) Limited Application of raman spectroscopy for the manufacture of inhalation powders
MX2021006869A (es) 2018-12-10 2021-07-02 Massachusetts Gen Hospital Esteres de cromolin y usos de los mismos.
EP4132507A4 (en) 2020-04-06 2024-05-15 The General Hospital Corporation METHODS FOR TREATING CORONAVIRUS-INDUCED INFLAMMATORY CONDITIONS
WO2022043481A1 (en) 2020-08-28 2022-03-03 Universität Linz Use of leoligin in the prevention of tissue damage

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1792207U (de) 1959-04-14 1959-07-16 Esslinger Sack Und Planenfabri Transportables gartenschwimm- oder -planschbecken mit aus kunststoff-folie bestehenden waenden.
FR1489749A (fr) 1965-03-25 1967-07-28 Fisons Pharmaceuticals Ltd Procédé de préparation de composés bis-chromonylés et leurs dérivés

Also Published As

Publication number Publication date
MY7400330A (en) 1974-12-31
DE1792207B2 (de) 1977-10-13
FI48973B (cg-RX-API-DMAC7.html) 1974-12-02
DK123276B (da) 1972-06-05
DE1792207C3 (de) 1978-06-29
DE1792207A1 (de) 1971-11-04
SE372420B (cg-RX-API-DMAC7.html) 1974-12-23
IE32343L (en) 1969-02-08
FR8142M (cg-RX-API-DMAC7.html) 1970-08-17
US3634582A (en) 1972-01-11
MY7400329A (en) 1974-12-31
NL161984B (nl) 1979-11-15
BE718846A (cg-RX-API-DMAC7.html) 1969-01-31
CA946280A (en) 1974-04-30
DE1792799A1 (de) 1977-08-11
FR1605538A (cg-RX-API-DMAC7.html) 1979-02-23
JPS5643448B1 (cg-RX-API-DMAC7.html) 1981-10-13
NL6811060A (cg-RX-API-DMAC7.html) 1969-02-11
GB1242211A (en) 1971-08-11
NL161984C (nl) 1980-04-15
NO128307B (cg-RX-API-DMAC7.html) 1973-10-29
FI48973C (fi) 1975-03-10

Similar Documents

Publication Publication Date Title
IE32343L (en) Powder composition
JP2974409B2 (ja) 微粒子薬物組成物
Zeng et al. The role of fine particle lactose on the dispersion and deaggregation of salbutamol sulphate in an air stream in vitro
CA2124568C (en) Method for producing microgranulated particle
EP0203768B1 (en) A therapeutic effervescent composition and a method of preparing the same
DE69915478T2 (de) Geschmacksmaskierung mittels croscarmellose
JP2550362B2 (ja) スプレードライしたアセトアミノフェン
US4757090A (en) Direct tableting acetaminophen compositions
KR840000226A (ko) 신규한 형태의 의약품의 제조방법
GB1381872A (en) Pharmaceutical compositions for inhalation
IE60652B1 (en) Spray dried ibuprofen
CA2166109A1 (en) Compositions for inhalation
CA2166891A1 (en) Method for making freeze dried drug dosage forms
CA2125685A1 (en) Powders for inhalation and process for preparing them
NO20001670L (no) Fremgangsmate for fremstilling av en smaksmaskert farmasoytisk blanding og smaksmaskert farmasoytisk blanding fremstilt ifolge denne fremgangsmaten, samt smaksmaskerte tyggbare tabletter
HU225964B1 (en) Moisture barrier film coating composition, method, and coated form
JPWO1994008709A1 (ja) 微細な造粒体の製造方法
CA2430318A1 (en) Powder formulation and method for producing the same
CA2008972A1 (en) Nifedipine-containing pharmaceutical compositions and process for the preparation thereof
US6391340B1 (en) Dry powder pharmaceutical formulation
KR20000070189A (ko) 0.28 내지 0.38 g/㎖의 유동 벌크 밀도를 갖는 테르부탈린 술페이트 함유 신규 흡입 제제, 그의 제조 방법 및 그의 용도
GB644081A (en) Improvements in pectin products and the process of making same
JPH0967247A (ja) 均一な微粒子製剤の製造方法
GB1511852A (en) Reconstitutable powders
GB1468815A (en) Pharmaceutical compositions